GSK doubled the money paid out to its shareholders, reaching more than EUR 5 billion.
Industry & EmploymentBelgium
- Omissions
- GSK does not publish a single 'total money paid to shareholders' figure; the >€5 billion results from adding dividends (~£2.6-2.7bn) to the £2 billion buyback, a calculation that mixes a per-share dividend with a multi-year buyback programme.
- The 'doubling' depends on the baseline: in 2024 GSK paid dividends only and had no buyback, so the doubling is driven mainly by the new £2 billion buyback announced with the FY2024 results, not by a doubling of the dividend itself (the dividend per share rose from 60p to 66p, +10%).
- Geographic scope is ambiguous: the figures above are GSK group figures (in GBP), whereas the Belgian subsidiary is reported separately — Le Vif/Trends reports €12.3 billion of dividends distributed by GSK in Belgium over the last two years, which would be a different (and much larger) scope than the claim's 'more than €5 billion'.
- Figures are denominated in pounds sterling and converted to euros; the euro equivalent varies with the GBP/EUR exchange rate.
- Sources describing GSK's 2025 and 2026 results were published before the 2026-10-20 session date, but the precise combination used by the speaker could not be identified in a single published source.